The frequency of hypoglycemia and cardiovascular disorders during therapy with sulfonylureas compared with other secretagogues: a systematic review
https://doi.org/10.14341/2072-0351-5684
Abstract
In this systematic review the analysis of hypoglycemia and cardio-vascular events was analyzed due to therapy by SU and other secretagenes. Accordingto more then 1400 publications from 1984 to 2009 there is no clear data of increasing hypoglycemia and cardio-vascular events by using micronisedglibenklamide (glyiburide) in comparison to other medications.
About the Authors
Aleksey Vadimovich Zilov
I.M.Sechenov Moscow Medical Academy, Moscow
Tatiana Borisovna Morgunova
I.M.Sechenov Moscow Medical Academy, Moscow
Anna Leont'evna Terekhova
I.M.Sechenov Moscow Medical Academy, Moscow
References
1. Bloomgarden Z.T. New and traditional treatment of glycemia in NIDDM // Diabetes Care. - 1996. - Mar; 19(3). - P. 295-299
2. Draeger K.E., Wernicke-Panten K., Lomp H.J. et al. Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide // Horm Metab Res. - 1996. - Sep;28(9). - P. 419-425.
3. Damsbo P., Clauson P., Marbury T.C., Windfeld K. A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients // Diabetes Care. - 1999. - May;22(5). - P. 789-794.
4. Rosenstock J., Corrao P.J., Goldberg R.B., Kilo C. Diabetes control in the elderly: a randomized, comparative study of glyburide versus glipizide in non-insulin-dependent diabetes mellitus //Clin Ther. - 1993. - Nov-Dec 15(6). - P. 1031-1040.
5. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years // B.M.J. - 1995. - Jan 14;310(6972). - P. 83-8.
6. Wolffenbuttel B.H., Landgraf R. A 1-year multicenter randomized double- blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group // Diabetes Care. - 1999 . - Mar;22(3). - P. 463-467.
7. Baba S., Nakagawa S., Takebe K., Goto Y., Maezawa H., Takeda R., Sakamoto N., Fukui I. Comparison of gliclazide and glibenclamide treatment in non-insulin-dependent diabetes // Tohoku J. Exp. Med. - 1983. - Dec;141 Suppl. - P. 693-706.
8. Harrower Andrew D.B. Comparative tolerability of sulfonylureas in diabetes mellitus // Drug Safety. - 2000. - Apr 22(4). - P. 313-320
9. Gangji A.S., Cukierman T., Gerstein H.C., Goldsmith C.H., Clase C.M. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. // Diabetes Care. - 2007. - Feb;30(2). - P. 389-394.
10. Fowler M.J. Diabetes treatment, part 2: oral agents for glycemic mamagement // Clinical Diabetes. - 2007. - 25(4). - P. 131-134.
11. Mooradian A.D. Drug therapy of non-insulin-dependent diabetes mellitus in the elderly // Drugs. - 1996. - Jun;51(6). - P. 931-41
12. Steven E. Kahn, M.B., Ch.B., Steven M. Haffner, M.D., Mark A. Heise, Ph.D., William H. Herman, M.D., M.P.H., Rury R. Holman, F.R.C.P., Nigel P. Jones, M.A., Barbara G. Kravitz, M.S., John M. Lachin, Sc.D., M. Colleen O'Neill, B.Sc., Bernard Zinman Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy // NEJM. - Volume 355. - P. 2427-2443.
13. Holstein A, Plaschke A, Egberts EH: Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide // Diabetes Metab Res Rev. - 2001. - Nov-Dec;17(6). - 467-473.
Review
For citations:
Zilov A.V., Morgunova T.B., Terekhova A.L. The frequency of hypoglycemia and cardiovascular disorders during therapy with sulfonylureas compared with other secretagogues: a systematic review. Diabetes mellitus. 2010;13(2):100-104. (In Russ.) https://doi.org/10.14341/2072-0351-5684
Views:
912
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
